Neuroscience

MIRA Pharmaceuticals’ Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at...

Lin Health to Collaborate with Mayo Clinic to Expand Access to Evidence-Based, Tech-Enabled Chronic Pain Care

Retraining the brain's neural circuitry through a behavioral health approach empowers people living with chronic pain to avoid costly and...

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is...

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...

Five to Flow® Unveils Next-Generation Wellness Wave® Diagnostic for Improved Workplace Wellness and Productivity, Supporting World Mental Health Day’s Workplace Well-Being Focus

The enhanced employee sentiment tool equips employees and leaders to address stress, burnout, disengagement, and turnover for lasting growth and...

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription...

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the...

error: Content is protected !!